Report Highlights

U.S. Crohn's Disease: Market Overview

The U.S. Crohn's disease market is among the most concentrated biologic therapeutic arenas globally, with an estimated 780,000 adults diagnosed and treatment spending exceeding USD 9.8 billion in 2024. Unlike the global market, where generic small molecules and corticosteroids still account for a large share of prescriptions, American demand is increasingly driven by advanced therapies. Anti-TNF biologics, IL-23 inhibitors, integrin blockers, and JAK inhibitors dominate treatment guidelines and reimbursement pathways.

Structurally, the market is shaped by site-of-care economics. Infusion therapies such as infliximab, vedolizumab, and ustekinumab are administered in hospital outpatient departments and freestanding infusion centers, while subcutaneous adalimumab and risankizumab pens and oral upadacitinib tablets move through specialty pharmacies. This split creates a payer dynamic distinct from most global markets, where pharmacy-channel pricing rules rarely dominate. Medicare Part B and Part D coverage decisions therefore determine channel share more than clinical preference does.

Growth Drivers in U.S. Crohn's Disease Treatment

Demand is anchored by rising incidence among adolescents and young adults, a trend the Crohn's and Colitis Foundation tracks closely. Medicare Part D out-of-pocket spending is capped at USD 2,000 in 2025 under the Inflation Reduction Act, rising to USD 2,100 in 2026, which lifts adherence for expensive oral and injectable regimens among older patients. Together these factors expand the treated population faster than prevalence alone.

Treat-to-target guidance is the second engine. Clinical practice increasingly prioritizes endoscopic remission, pushing gastroenterologists to escalate earlier to agents such as AbbVie's Skyrizi, approved for Crohn's disease in 2022, and Takeda's Entyvio. A third driver is the expanding commercial pipeline, with Merck's tulisokibart in phase 3 development for Crohn's disease adding future competition and therapeutic options.

Market Restraints and Entry Barriers

Incumbent advantage is the dominant barrier. AbbVie's Humira franchise, once the top-selling drug globally, still anchors gastroenterology formularies through rebate contracts with major pharmacy benefit managers, and adalimumab biosimilars only gained meaningful access after 2023 private-label arrangements. New entrants must win preferred placement against bundled multi-indication contracts, which compresses net pricing for any novel agent.

Regulatory and reimbursement complexity compounds the barrier. Crohn's programs require multi-year phase 3 trials with endoscopic endpoints, often exceeding USD 200 million in cost, and BPCIA biosimilar pathways demand analytical comparability data that adds time and expense. Medicare Part B pays infused drugs at average sales price plus add-on payment, leaving hospital outpatient providers thin margins on biosimilars and slowing uptake of newer infused entrants.

Market Opportunities in the United States

Biologic-experienced patients with moderate-to-severe disease represent the most accessible near-term pool, estimated at roughly 200,000 U.S. adults. Subcutaneous maintenance formulations of IL-23 and integrin agents give entrants a route into home-injection care, a channel where Takeda's Entyvio pen and AbbVie's Skyrizi on-body injector already compete. Hub services bundling injection training and reimbursement support allow entrants to capture share from infusion-center dependency.

Pediatric Crohn's disease represents a second underserved opening. Few biologics carry pediatric labeling, and sponsors completing FDA Written Request studies under the Best Pharmaceuticals for Children Act earn six months of additional market exclusivity. Securing pediatric labeling alongside adult approval addresses an estimated USD 700 million pediatric and young adult spending pool by 2028.

Market at a Glance

Leading Market Participants

• AbbVie
• Johnson & Johnson
• Takeda
• Eli Lilly
• Pfizer
• Merck
• Amgen
• Celltrion
• Samsung Bioepis
• Sandoz

Regulatory and Policy Environment

The FDA's Center for Drug Evaluation and Research reviews Crohn's biologics under Biologics License Applications governed by the Biologics Price Competition and Innovation Act, with standard review targeting ten months after a sixty-day filing period. Biosimilars require interchangeability designation under FDA's interchangeability guidance to allow pharmacy-level substitution in states with substitution statutes. Medicare drug price negotiation under the Inflation Reduction Act applies to qualifying Part B biologics after eligibility windows close, with first Part B selections affecting prices from 2028.

The Centers for Medicare and Medicaid Services administers the Part D redesign, capping beneficiary out-of-pocket costs at USD 2,000 in 2025 and USD 2,100 in 2026. The 340B Drug Pricing Program offers discounts to qualifying hospitals and clinics that dispense infused biologics, altering contracting economics. Companies must also comply with the Physician Payments Sunshine Act, which requires public reporting of payments to physicians, and FDA's DSCSA product tracing standards.

Long-Term Outlook for U.S. Crohn's Disease Treatment

By 2032 the U.S. market is forecast to reach USD 15.6 billion, with originator IL-23 and JAK franchises holding larger shares as ustekinumab and adalimumab erosion stabilizes. Payers will continue to favor lower-cost biosimilars for biologic-naive patients, which reshapes the early-line treatment mix. Subcutaneous home therapy will account for a growing proportion of maintenance prescriptions over the period.

Competitive intensity will rise as Merck's tulisokibart and other late-stage programs reach market. Winners will combine interchangeable biosimilar strategies in mature classes with differentiated subcutaneous or oral profiles in newer ones, while IRA negotiation reshapes Part B economics after 2028. Entrants that secure formulary access by 2028 will hold positions for the remainder of the forecast period.